Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Koshiar, Ruzica Livaja ^a   Somajo, Sofia ^a   Norström, Eva ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; CALCIMYCIN; LACTADHERIN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE; PROTEIN ANTIBODY; PROTEIN S; TENASE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; BLOOD CLOTTING FACTOR 5; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; MEMBRANE ANTIGEN; MFGE8 PROTEIN, HUMAN; MILK PROTEIN; PROTEIN C; PROTHROMBINASE COMPLEX; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CELL ISOLATION; CELL STIMULATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROCYTE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE MICROPARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; MEMBRANE MICROPARTICLE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; ULTRACENTRIFUGATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD CLOTTING TEST; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM;

ANNEXIN A5; ANTIBODIES; ANTIGENS, SURFACE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALCIMYCIN; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; ERYTHROCYTES; FACTOR V; FACTOR VA; FACTOR VIIIA; FACTOR XA; HUMANS; LIPOPROTEINS; MILK PROTEINS; PHOSPHATIDYLSERINES; PROTEIN C; PROTEIN S; THROMBIN; THROMBOPLASTIN; ULTRACENTRIFUGATION;

EID: 84927552343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104200     Document Type: Article

References (54)

1. Inal JM, Ansa-Addo EA, Stratton D, Kholia S, Antwi-Baffour SS, et al. (2012) Microvesicles in health and disease. Archivum immunologiae et therapiae experimentalis 60: 107-121.
2. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A (2009) Cell-derived microparticles in haemostasis and vascular medicine. Thrombosis and haemostasis 101: 439-451.
3. Horstman LL, Ahn YS (1999) Platelet microparticles: a wide-angle perspective. Critical reviews in oncology/hematology 30: 111-142. (Pubitemid 29232249)
4. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, et al. (2001) Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thrombosis and haemostasis 85: 639-646. (Pubitemid 32293699)
5. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, et al. (2001) Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thrombosis and haemostasis 85: 810-820. (Pubitemid 32421813)
6. Rubin O, Delobel J, Prudent M, Lion N, Kohl K, et al. (2013) Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion 53: 1744-1754.
7. Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, et al. (2012) The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thrombosis and haemostasis 107: 1044-1052.
8. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ (1989) Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. The Journal of biological chemistry 264: 17049-17057. (Pubitemid 19255533)
9. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, et al. (1991) Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 77: 2641-2648.
10. Hoffman M, Monroe DM, Roberts HR (1992) Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thrombosis and haemostasis 68: 74-78.
11. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, et al. (1991) Platelet-derived microparticles express high affinity receptors for factor VIII. The Journal of biological chemistry 266: 17261-17268. (Pubitemid 21907934)
12. Ahmad SS, London FS, Walsh PN (2003) Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface. J Thromb Haemost 1: 2348-2355.
13. Dahlback B, Villoutreix BO (2005) Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arteriosclerosis, thrombosis, and vascular biology 25: 1311-1320. (Pubitemid 40923345)
14. Eldor A, Rachmilewitz EA (2002) The hypercoagulable state in thalassemia. Blood 99: 36-43.
15. Hugel B, Socie G, Vu T, Toti F, Gluckman E, et al. (1999) Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 93: 3451-3456. (Pubitemid 29220912)
16. van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, et al. (2009) Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94: 1513-1519.
17. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, et al. (2012) Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 10: 1355-1362.
18. Lane PA, O'Connell JL, Marlar RA (1994) Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. American journal of hematology 47: 295-300. (Pubitemid 24372284)
19. Bezeaud A, Venisse L, Helley D, Trichet C, Girot R, et al. (2002) Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C. British journal of haematology 117: 409-413. (Pubitemid 34451158)
20. Somajo S, Koshiar RL, Norstrom E, Dahlback B (2014) Protein S and factor V in regulation of coagulation on platelet microparticles by activated protein C. Thrombosis research.
21. Malm J, Cohen E, Dackowski W, Dahlback B, Wydro R (1990) Expression of completely gamma-carboxylated and beta-hydroxylated recombinant human vitamin-K-dependent protein S with full biological activity. European journal of biochemistry/FEBS 187: 737-743.
22. Dahlback B (1980) Human coagluation factor V purification and thrombin-catalyzed activation. The Journal of clinical investigation 66: 583-591.
23. Fujikawa K, Legaz ME, Davie EW (1972) Bovine factors X 1 and X 2 (Stuart factor). Isolation and characterization. Biochemistry 11: 4882-4891.
24. Nelsestuen GL, Suttie JW (1973) The mode of action of vitamin K. Isolation of a peptide containing the vitamin K-dependent portion of prothrombin. Proceedings of the National Academy of Sciences of the United States of America 70: 3366-3370.
25. Shen L, Shah AM, Dahlback B, Nelsestuen GL (1997) Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. Biochemistry 36: 16025-16031. (Pubitemid 28065016)
26. Lundblad RL, Uhteg LC, Vogel CN, Kingdon HS, Mann KG (1975) Preparation and partial characterization of two forms of bovine thrombin. Biochemical and biophysical research communications 66: 482-489.
27. Rubin O, Crettaz D, Canellini G, Tissot JD, Lion N (2008) Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. Vox sanguinis 95: 288-297.
28. Hou J, Fu Y, Zhou J, Li W, Xie R, et al. (2011) Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox sanguinis 100: 187-195.
29. Norstrom E, Thorelli E, Dahlback B (2002) Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 100: 524-530. (Pubitemid 34761115)
30. Sun YH, Tran S, Norstrom EA, Dahlback B (2004) Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by Gla domain-mutated human-activated protein C. The Journal of biological chemistry 279: 47528-47535. (Pubitemid 39540897)
31. Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, et al. (1995) Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. The Journal of biological chemistry 270: 21158-21166.
32. Dahlback B, Hildebrand B, Malm J (1990) Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. The Journal of biological chemistry 265: 8127-8135.
33. Nantakomol D, Dondorp AM, Krudsood S, Udomsangpetch R, Pattanapanyasat K, et al. (2011) Circulating red cell-derived microparticles in human malaria. The Journal of infectious diseases 203: 700-706.
34. Pattanapanyasat K, Noulsri E, Fucharoen S, Lerdwana S, Lamchiagdhase P, et al. (2004) Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry Part B, Clinical cytometry 57: 23-31. (Pubitemid 38297620)
35. Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, et al. (2009) Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care 13: R151.
36. Koch CG, Figueroa PI, Li L, Sabik JF, 3rd, Mihaljevic T, et al. (2013) Red blood cell storage: how long is too long? The Annals of thoracic surgery 96: 1894-1899.
37. Canellini G, Rubin O, Delobel J, Crettaz D, Lion N, et al. (2012) Red blood cell microparticles and blood group antigens: an analysis by flow cytometry. Blood transfusion=Trasfusione del sangue 10 Suppl 2: s39-45.
38. Salzer U, Zhu R, Luten M, Isobe H, Pastushenko V, et al. (2008) Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin. Transfusion 48: 451-462. (Pubitemid 351294572)
39. Allan D, Thomas P, Limbrick AR (1980) The isolation and characterization of 60 nm vesicles ('nanovesicles') produced during ionophore A23187-induced budding of human erythrocytes. The Biochemical journal 188: 881-887. (Pubitemid 10023637)
40. Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. The American journal of medicine 115: 721-728. (Pubitemid 38032666)
41. Norstrom EA, Steen M, Tran S, Dahlback B (2003) Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va. The Journal of biological chemistry 278: 24904-24911. (Pubitemid 37548650)
42. Norstrom EA, Tran S, Steen M, Dahlback B (2006) Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. The Journal of biological chemistry 281: 31486-31494. (Pubitemid 46041413)
43. Ahnstrom J, Andersson HM, Canis K, Norstrom E, Yu Y, et al. (2011) Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue. Blood 117: 6685-6693.
44. Hackeng TM, Sere KM, Tans G, Rosing J (2006) Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proceedings of the National Academy of Sciences of the United States of America 103: 3106-3111. (Pubitemid 43346432)
45. Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng TM (2010) Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 8: 294-300.
46. Wood JP, Ellery PE, Maroney SA, Mast AE (2014) Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. Arteriosclerosis, thrombosis, and vascular biology 34: 169-176.
47. Ndonwi M, Tuley EA, Broze GJ, Jr. (2010) The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 116: 1344-1351.
48. Ahnstrom J, Andersson HM, Hockey V, Meng Y, McKinnon TA, et al. (2012) Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 120: 5059-5062.
49. Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, et al. (2007) Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 109: 1931-1937. (Pubitemid 46348189)
50. Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr. (1988) Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72: 2020-2025. (Pubitemid 19030892)
51. Tracy PB, Eide LL, Bowie EJ, Mann KG (1982) Radioimmunoassay of factor V in human plasma and platelets. Blood 60: 59-63. (Pubitemid 12085920)
52. Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, et al. (2013) Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. The Journal of clinical investigation 123: 3777-3787.
53. Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, et al. (2008) Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 112: 3615-3623.
54. Piccin A, Murphy C, Eakins E, Kinsella A, McMahon C, et al. (2012) Protein C and free protein S in children with sickle cell anemia. Annals of hematology 91: 1669-1671.